Loading…
← CockpitCompetitor Analysis › JUBLPHARMA.NS Jubilant PharmovaOpen in the cockpit ↗

Jubilant PharmovaJUBLPHARMA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Diversified pharma company running CDMO manufacturing, specialty generics and radiopharmaceuticals under the Jubilant Bhartia Group.

≈ A diversified Indian CDMO/radiopharma conglomerate armMomentum neutral 55
Mkt cap
$1.59B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$1.00M
20-day average traded
Fwd P/E
29.0×
forward earnings
ROIC−WACC
-8.9 pp
WACC 13.4%
Hurdle
n/a
no reverse DCF
Next earnings
79 days
5 Feb 2027
Close · INR₹933.60
1D-2.2%
1W-5.5%
1M-0.2%
3M+7.8%
6M-7.7%
YTD-13.0%
1Y-18.1%
ATR %3.4%
Beta0.55
52w lowhigh19.7% off high

What Jubilant Pharmova does

Diversified pharma company running CDMO manufacturing, specialty generics and radiopharmaceuticals under the Jubilant Bhartia Group.

Spread across services and products: its US contract manufacturing, with sterile injectables and allergy products from a Spokane, Washington plant, works for other drug companies, while its radiopharmacy business supplies hospitals with diagnostic isotopes. The group has been working to reduce debt.

In one line: A diversified Indian CDMO/radiopharma conglomerate arm.

Products and services

  • CDMO/contract manufacturing
  • Specialty generics
  • Radiopharmaceuticals (DraxImage)
  • Allergy therapy products

Customers

  • Global pharma/biotech partners
  • Hospitals/imaging centers (radiopharma)

Where it sits in the supply chain

  • CDMO manufacturing
  • Specialty pharma/generics
  • Radiopharmaceuticals (imaging agents)

What could go right

  • Radiopharma/CDMO demand growth
  • Debt reduction improving margins

What could go wrong

  • High leverage/legacy debt
  • Segment complexity/capital allocation

Moat: narrow (regulatory licence, process know-how). Radiopharma manufacturing/distribution licences and CDMO plants are difficult and slow to replicate.

Headquarters: Noida, India · Founded: 2020 · Employees: 6,386

Named competitors

Jubilant Pharmova at a glance

Size Jubilant Pharmova (JUBLPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.59B, the 455th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹933.60 on 18 Nov 2026.

Performance Over six months the shares fell 7.7%, against -9.1% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 18.3% over the last twelve months (peer median +6.6%); the operating margin is 6.8% (peer median 12.4%).

Valuation It trades at 29.0× forward earnings against a peer median of 23.8× (6th most expensive of 15).

Capital Return on invested capital runs 8.9 points below its cost of capital (13.4% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026JUBLPHARMA.NS 92Peer median 92
Six months, rebased to 100: Jubilant Pharmova against the median of its 20 peers (local-currency closes).

Jubilant Pharmova financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹90.1B₹82.7B₹72.3B₹67.0B₹62.6B
Revenue growth—+14%+8%+7%—
Gross profit₹25.2B₹17.3B₹16.5B₹13.6B₹9.81B
EBITDA₹11.2B₹12.1B₹10.4B₹8.96B₹7.61B
Net income₹2.63B₹3.98B₹8.39B₹771M-₹610M
Free cash flown/a-₹4.36B-₹2.41B-₹1.44B-₹3.78B
Capital expendituren/a₹14.5B₹11.2B₹8.98B₹8.14B
Total debt₹43.0B₹36.1B₹27.3B₹36.6B₹36.8B

Quarterly statements and history in the cockpit →

Jubilant Pharmova competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%+20%002675600420002755301047002019ANURASASTRAZEN000766SRPT1681600572603235300357298380INDGN600993CAPLIPOINT300723FAEJUBLPHARMA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Jubilant Pharmova is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×002675600420002755301047002019ANURAS1681600572300357INDGN600993CAPLIPOINT300723FAEJUBLPHARMA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jubilant Pharmova is the large dot.

Jubilant Pharmova competitors and peer comparison

Head to head with its named competitors (JUBLPHARMA.NS vs PPLPHARMA.NS vs SYNGENE.NS vs LNTH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jubilant Pharmova JUBLPHARMA.NS$1.59B-8%+18%7%29.0×n/a
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a
Syngene International SYNGENE.NS$1.88B-8%-6%13%70.7×36.4%
Lantheus LNTH$6.67B+6%+2%19%15.5×0.4%

How Jubilant Pharmova compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jubilant Pharmova against its 20 peers (data as of 18 Nov 2026)
MeasureJUBLPHARMA.NSPeer medianRank in peer set
1-month return-0.2%-4.6%7th highest of 21
6-month return-7.7%-9.1%10th highest of 20
Distance from 52-week high-19.7%-33.2%7th highest of 21
Revenue growth (TTM)+18.3%+6.6%6th highest of 20
Operating margin6.8%12.4%5th lowest of 20
Forward P/E29.0×23.8×6th most expensive of 15
ROIC minus cost of capital-8.9 pp+1.2 pp5th lowest of 21
EV / EBITDA16.1×19.8×3rd cheapest of 7
Net debt / EBITDA2.8×-1.1×3rd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%

Questions

Who are Jubilant Pharmova's main competitors?
Named competitors: Piramal Pharma (PPLPHARMA.NS), Syngene International (SYNGENE.NS), Lantheus Holdings (LNTH). The cockpit's measured peer set (industry) also includes Yantai Dongcheng Biochemicals (002675.SZ), Shanghai Shyndec Pharmaceutical (600420.SS), Beijing Aosaikang Pharmaceutical (002755.SZ), Sino Biological (301047.SZ), Yifan Pharmaceutical (002019.SZ), Anupam Rasayan India (ANURAS.NS).
Is Jubilant Pharmova expensive compared with its peers?
On forward p/e it trades at 29.0× against a peer median of 23.8×, 6th most expensive of 15 in its peer set.
How has Jubilant Pharmova stock performed?
Over six months to 18 Nov 2026 the shares returned -7.7% against -9.1% for the median peer; over one year -18.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.